Zepbound

Chronic Weight Management

Zepbound is a prescription medication used for long-term weight management in adults. It is specifically approved for use in the following groups:

• Adults with obesity, defined as a body mass index (BMI) of 30 kg/m² or greater.
• Adults who are overweight (BMI of 27 kg/m² or greater) and have at least one weight-related health condition.

Common weight-related conditions that may qualify an overweight individual for Zepbound include:

• High blood pressure (hypertension)
• Type 2 diabetes
• High cholesterol (dyslipidemia)
• Obstructive sleep apnea

Obstructive Sleep Apnea

Zepbound is also indicated for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.

Lifestyle Integration

Zepbound is not intended to be used alone. It must be used in combination with a reduced-calorie diet and increased physical activity to be effective for weight loss and maintenance.

Hormone Mimicry

Zepbound contains the active ingredient tirzepatide, which is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. These are hormones naturally produced by the intestines after a person eats.

Appetite and Fullness

The medication targets specific receptors in the brain that control hunger and satiety. By activating these receptors, Zepbound helps reduce feelings of hunger and increases the sensation of being full. This helps individuals consume fewer calories by feeling satisfied with smaller portions of food.

Slowing Digestion

Zepbound also affects the digestive system by slowing down gastric emptying. This means food stays in the stomach for a longer period of time, which contributes to a prolonged feeling of fullness after a meal.

Blood Sugar Regulation

While primarily used for weight management, the medication also influences how the body processes sugar. It works by:

• Stimulating the pancreas to release insulin when blood sugar levels are elevated.
• Reducing the amount of sugar the liver produces and releases into the bloodstream.
• Improving the body's overall sensitivity to insulin.

Common Side Effects

The most frequently reported side effects of Zepbound are related to the digestive system. These symptoms are often most noticeable when first starting the medication or after a dose increase. Common side effects include:

• Nausea and vomiting
• Diarrhea or constipation
• Stomach pain and indigestion
• Heartburn or belching
• Fatigue
• Injection site reactions, such as redness or swelling
• Hair loss

Serious Side Effects

Zepbound may cause serious complications that require immediate medical evaluation. These include:

• Pancreatitis: Severe pain in the stomach area that may move to the back.
• Gallbladder problems: Symptoms such as pain in the upper stomach, fever, or yellowing of the skin and eyes.
• Kidney problems: Often caused by dehydration from severe vomiting or diarrhea.
• Severe allergic reactions: Symptoms like swelling of the face or throat, dizziness, or difficulty breathing.
• Low blood sugar: Risk increases if taken with other diabetes medications.
• Vision changes: New or worsening vision problems.
• Severe stomach issues: Problems with the stomach emptying properly (gastroparesis).

Thyroid C-cell Tumors

In animal studies, tirzepatide (the active ingredient in Zepbound) caused thyroid C-cell tumors. It is unknown whether Zepbound causes these tumors, including medullary thyroid carcinoma (MTC), in humans. This medication is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Patients should be aware of potential symptoms such as a lump in the neck, hoarseness, or difficulty swallowing.

Severe Gastrointestinal Disease

Zepbound is associated with gastrointestinal adverse reactions, sometimes severe. It has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended for these individuals.

Pancreatitis and Gallbladder Problems

• Pancreatitis: Acute pancreatitis has been reported in clinical trials. If pancreatitis is suspected, the medication should be discontinued.
• Gallbladder Disease: Rapid weight loss can increase the risk of cholelithiasis (gallstones) or cholecystitis (gallbladder inflammation). If these conditions are suspected, diagnostic studies and appropriate follow-up are necessary.

Kidney Function

Severe gastrointestinal reactions, such as nausea, vomiting, and diarrhea, may lead to dehydration. This dehydration can cause acute kidney injury. Monitoring kidney function is recommended when starting or increasing doses in patients who report severe gastrointestinal distress.

Hypoglycemia Risk

While Zepbound is not a primary treatment for diabetes, using it alongside insulin or insulin secretagogues (such as sulfonylureas) increases the risk of hypoglycemia (low blood sugar). A lower dose of the concomitant insulin or secretagogue may be required to reduce this risk.

Hypersensitivity and Vision Changes

• Serious Allergic Reactions: Severe hypersensitivity reactions, including anaphylaxis and angioedema, have occurred. If a reaction is suspected, the medication must be stopped immediately.
• Diabetic Retinopathy: In patients with type 2 diabetes, rapid improvement in glucose control has been associated with the temporary worsening of diabetic retinopathy.

Mental Health Monitoring

Suicidal ideation and behavior have been reported with other weight management medications. Healthcare providers typically monitor patients for the emergence or worsening of depression, suicidal thoughts, or any unusual changes in mood or behavior.

Pregnancy

Zepbound is not recommended for use during pregnancy. Weight loss is generally not advised for pregnant individuals, as it may harm the developing fetus. Animal studies have shown that tirzepatide, the active ingredient in Zepbound, may cause fetal harm and lead to lower birth weights.

If you become pregnant while taking this medication, you should contact your healthcare provider immediately to discuss stopping the treatment.

Contraception

Zepbound can slow the absorption of oral contraceptive pills, potentially making them less effective. If you use birth control pills, your healthcare provider may recommend:

• Switching to a non-oral contraceptive method, such as a patch or vaginal ring.
• Using a backup barrier method, such as condoms, for four weeks after starting the medication and for four weeks after each dose increase.

Breastfeeding

It is not known if Zepbound passes into breast milk or if it affects a nursing infant. Because of the potential for adverse reactions, you should discuss the risks and benefits of breastfeeding while using this medication with your healthcare provider.

Planning Pregnancy

If you are planning to become pregnant, your doctor may advise you to stop taking Zepbound at least two months before conception to ensure the medication is fully cleared from your body.

Dosage Forms

Zepbound is provided as a clear solution for injection under the skin. It is available in two types of containers:

• Single-dose pre-filled pens: These are disposable devices used for administration.
• Single-dose vials: These containers hold the medication for use with a syringe.

The injection is typically given in the abdomen, thigh, or the back of the upper arm.

FDA Approval and Indications

Zepbound (tirzepatide) was first approved by the FDA in November 2023 for chronic weight management. It is intended for use in adults with obesity (a body mass index of 30 or higher) or those who are overweight (a body mass index of 27 or higher) and have at least one weight-related medical condition, such as type 2 diabetes, high blood pressure, or high cholesterol. It is meant to be used alongside a reduced-calorie diet and increased physical activity.

In June 2024, the FDA expanded the approved use of Zepbound to include the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity.

Boxed Warning

Zepbound carries a boxed warning regarding the risk of thyroid C-cell tumors. This warning is based on studies in rodents where tirzepatide caused thyroid tumors; however, it is not yet known if it causes similar tumors in humans. The medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or in patients with Multiple Endocrine Neoplasia syndrome type 2.

Regulatory Monitoring

The FDA continues to monitor the safety and marketing of Zepbound. This includes issuing warnings regarding promotional materials that may minimize the risks associated with the drug or provide misleading information about its benefits.

How Zepbound Works for Weight Loss

Zepbound contains the active ingredient tirzepatide. It is the first medication in a class that targets two different hormone receptors: glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). These hormones are naturally produced by the body to regulate appetite and food intake.

By mimicking these hormones, Zepbound helps with weight loss in several ways:

• It signals the brain to increase feelings of fullness and decrease hunger.
• It slows down the rate at which the stomach empties, which helps you feel satisfied for longer after eating.
• It helps regulate how the body processes sugar and fat.

Eligibility and Use

The FDA has approved Zepbound for adults who meet specific body mass index (BMI) criteria:

• A BMI of 30 kg/m² or greater (obesity).
• A BMI of 27 kg/m² or greater (overweight) in the presence of at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol.

Zepbound is intended to be used as a long-term treatment alongside a reduced-calorie diet and increased physical activity. It is administered once weekly as an injection under the skin of the abdomen, thigh, or upper arm.

Effectiveness

Clinical studies have shown that Zepbound can lead to significant weight reduction. In trials, participants taking the highest doses of tirzepatide lost a substantial percentage of their initial body weight compared to those taking a placebo. However, individual results vary, and the medication must be used consistently with lifestyle changes to maintain weight loss.